Literature DB >> 12472678

Structural, quantitative and functional comparison of amyloid P component in sera from patients with systemic lupus erythematosus and healthy donors.

J W Sen1, C Recke, L Rahbek, K Skogstrand, N H H Heegaard.   

Abstract

Serum amyloid P component (SAP) is a serum protein that has a function as opsonin and is known to bind nuclear material with high affinity. Quantitative and/or qualitative deficiencies in SAP may possibly lead to the impairment of normal homoeostatic mechanisms of tissue turnover. Thus, SAP knockout mice display systemic lupus erythematosus (SLE)-like manifestations such as nephritis and circulating antinuclear antibodies. In the present study, we investigated whether there are changes in the structure, function or serum levels of SAP in serum from SLE patients as compared with those from healthy donors. We found that SAP in SLE sera has the same molecular mass as that of in the sera of normal individuals, when analysed by online immunoaffinity reversed phase mass spectrometry. Also, the serum levels of SAP did not differ significantly between the two groups. Finally, as an estimate of function, SAP from SLE patients appeared to have the same affinity for heparin and nucleosomes as SAP from normal individuals, when analysed by crossed affinity immunoelectrophoresis and enzyme-linked immunosorbent capture assay (ELISA). In conclusion, the data do not support alterations in the levels, structure or function of SAP circulating in SLE patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12472678     DOI: 10.1046/j.1365-3083.2002.01178.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  4 in total

1.  Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.

Authors:  G Zandman-Goddard; M Blank; P Langevitz; L Slutsky; M Pras; Y Levy; O Shovman; T Witte; A Doria; J Rovensky; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

2.  Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction.

Authors:  M Bijl; H Bootsma; Y Van Der Geld; P C Limburg; C G M Kallenberg; M H Van Rijswijk
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 3.  Glycosaminoglycan Neutralization in Coagulation Control.

Authors:  Amélie I S Sobczak; Samantha J Pitt; Alan J Stewart
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-04-19       Impact factor: 8.311

Review 4.  The Development of Serum Amyloid P as a Possible Therapeutic.

Authors:  Darrell Pilling; Richard H Gomer
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.